Amarin petitions Supreme Court to revive Vascepa patents
18-02-2021
Ruling opens door for Noven’s oestrogen patch generics
10-09-2020
FDA approves Dr Reddy’s Vascepa generic
13-08-2020
Pavel Kapysh / Shutterstock.com
Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa (icosapent ethyl).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amarin, Vascepa, en banc, Federal Circuit, heart medicine, invalidated patents, FDA, generics, Hikma, remedies, appeal, global market, healthcare
